Outcomes of Pancreatic Cancer Treatment in Saudi Arabia
Author Information
Author(s): Aseafan Mohamed, Alfakeeh Ali H., Tashkandi Emad, Mahrous Mervat, Alghamdi Mohammed, Alshamsan Bader, Al-Hajeili Marwan, Bakhsh Safwan, Alshammari Kanan, Almugbel Fahad A., Alfagih Abdulhameed H., Allehebi Ahmed, Montaser Mohamed, Elsafty Mohamed Hamdy, Elnaghi Khaled Abd Elaziz, Issa Ibrahim, Bakshi Eesa, AlSubaie Sadeem, AlMutairi Bandar, Mokhtar Hoda, Aboelatta Mohamed, Bukhari Nedal, Alzahrani Ali M., Elhassan Tusneem, Alqahtani Ali, Bazarbashi Shouki
Primary Institution: Security Forces Hospital, Riyadh, Saudi Arabia
Hypothesis
This study aimed to evaluate the real-world clinical characteristics, treatment patterns, and outcomes of patients with locally advanced unresectable and de-novo metastatic pancreatic ductal adenocarcinoma in Saudi Arabia.
Conclusion
The study confirms that clinical outcomes for locally advanced unresectable and metastatic pancreatic cancer in Saudi Arabia are consistent with international data, with FOLFIRINOX showing superior outcomes over gemcitabine-based regimens.
Supporting Evidence
- 63% of patients presented with multiple metastatic sites, primarily in the liver.
- The median OS was 10.34 months for the entire cohort.
- FOLFIRINOX was the most common first-line treatment (55.1%).
- 7.1% of patients had deficient mismatch repair (d-MMR).
- 5.8% of patients harbored BRCA mutations.
Takeaway
This study looked at how patients with a serious type of pancreatic cancer are treated in Saudi Arabia and found that the treatments work similarly to those in other countries.
Methodology
This is a retrospective, multicentre study involving 350 patients diagnosed with unresectable locally advanced or de-novo metastatic PDAC between January 2015 and November 2023.
Potential Biases
Variability in treatment protocols across centers may influence outcomes.
Limitations
The study is retrospective, treatment choices were made by different physicians without clear criteria, and some prognostic factors were not examined due to lack of data.
Participant Demographics
{"median_age":60,"sex_distribution":{"female":129,"male":221},"comorbidities":{"diabetes":199,"hypertension":155}}
Statistical Information
P-Value
p≤0.001
Confidence Interval
{"median_PFS":"95% CI 4.48–6.16","median_OS":"95% CI 9.32–11.37"}
Statistical Significance
p≤0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website